Indegene Builds Tech Suite, Outcomes Play With Skura Deal
Healthcare solutions provider Indegene expects its acquisition of Skura Corporation's life science business to expand its multi-channel technology suite and scale up product development capabilities in North America, positioning it for leadership in the "Outcome-as-a-Service" category.
You may also be interested in...
RiKen gets $9.3m up front plus potential milestones and royalties for use of its aAVC technology, while retaining research rights to the platform. JW Pharmaceutical acquires Vietnam’s Euvipharm.
More than half a dozen generic rivaroxaban brands are now available in India, putting the heat on Bayer’s blockbuster anticoagulant Xarelto in the price-sensitive market. Many rival generics are priced over 50% lower than the innovator product.
Dr Reddy’s signals a sharp step up in ambitions at home, propelled by building leadership in 10 therapy segments and an “India-first” approach for specialty products. Uptick in the China business and the potential launch of a Russia-partnered COVID-19 vaccine were other aspects of the business discussed at JPM.